EPZ-5676: Clinical Trials

4 trials of EPZ-5676, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Terminated 1
Phase 22Completed 1, Terminated 1

Follow EPZ-5676: new trials by email Literature Review of EPZ-5676 trials Research Report on EPZ-5676

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement
Azacitidine, Pinometostat - Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Leukemia Cutis
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)12020-03-062023-10-18
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
Cytarabine, Daunorubicin, Daunorubicin Hydrochloride - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)62019-04-102025-06-18
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
EPZ-5676 - Leukemia, Acute Myeloid Leukemia
Phase 1CompletedEpizyme, Inc.182014-05-012023-06-18
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
EPZ-5676 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 1CompletedEpizyme, Inc.512012-09-012024-03-26

Conditions studied

Leukemia, Myeloid, Acute (4)  ·  Leukemia (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Myelodysplastic Syndromes (1)  ·  Myeloproliferative Disorders (1)

Sponsors

Epizyme, Inc. (2)  ·  National Cancer Institute (NCI) (2)

Countries

United States (4)  ·  Canada (1)  ·  Germany (1)  ·  Netherlands (1)

Top investigators

Cynthia Wetmore, MD PhD (1)  ·  David A Rizzieri, MD (1)  ·  Guillermo Garcia-Manero, MD (1)  ·  James S Blachly (1)  ·  Jessica Altman, MD (1)  ·  Jesus Berdeja, MD (1)  ·  Jim A Whitlock, MD (1)  ·  Kamal Menghrajani (1)  ·  Lewis Silverman, MD (1)  ·  Lia Gore, MD (1)  ·  Martin S. Tallman, MD (1)  ·  Maureen O'Brien, MD (1)  ·  Mignon Loh, MD (1)

Results publications

PMID 29724899

NIH funding

UM1CA186691 (1), UM1CA186712 (1)